Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F012 - Psoriasis and Atopic Dermatitis: Advances in Therapy and Comorbidities

Friday, February 16; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate recent data of comorbidities in psoriasis and atopic dermatitis.
  • Discuss emerging therapies for psoriasis and atopic dermatitis.


Psoriasis and atopic dermatitis are common, immune-mediated chronic diseases that have emerging therapeutic options (topical, oral, biologic, biosimilar). We will discuss optimal labs before starting therapy and labs while patients are on systemic therapy. We will compare and contrast comorbidities of these two conditions.


  • Egeberg, Alexander, MD, PhD: Eli Lilly and Company – C(H), I(Grants/Research Funding), SP(H), Speaker/Faculty Education(H); Galderma Laboratories, L.P. – SP(H); Janssen-Cilag – SP(H); Novartis – SP(H); Pfizer Inc. – I(Grants/Research Funding), SP(H);
  • Koo, John Y. M., MD: AbbVie – SP(H); Celgene Corporation – SP(H); Eli Lilly and Company – C(Fees); Janssen Pharmaceuticals, Inc – SP(H); Leo Pharma Inc. – SP(H); Novartis Pharmaceuticals Corp. – SP(H); Ortho Dermatologics – SP(H); Pfizer Inc. – C(Fees); Regeneron – SP(H); Sanofi – SP(H); Sun Pharmaceutical Industries Ltd. – SP(H); UCB – SP(H);
  • Silverberg, Jonathan I., MD, PhD, MPH: AbbVie – C(H), I(NC); AnaptysBio – C(H); Asana Biosciences, LLC – C(H); Dermira – A(H); Eli Lilly and Company – C(H), I(NC); Galderma Research & Development, LLC – C(H); GlaxoSmithKline – C(H), I(NC); Glenmark Generics Inc. – C(H); Kiniksa Pharmaceuticals, Ltd. – C(H), I(NC); Leo Pharma Inc – A(H); Leo Pharma Inc. – I(H); Medimmune – C(H); Menlo Therapeutics – A(H), I(NC); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC), SP(H); Sanofi – C(Grants/Research Funding);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees), I(Grants/Research Funding); Boehringer Ingelheim – C(Fees); Demira – C(Fees); Dermavant Sciences – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Forte Biosciences – C(Fees); Galderma Laboratories, LP – I(Grants/Research Funding); Incyte Corporation – C(Fees); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc. – C(Fees), I(Grants/Research Funding); Menlo Therapeutics Inc. – C(Fees); Merck – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Sanofi Genzyme – C(Fees); Valeant Pharmaceuticals International – C(Fees);
  • Wu, Jashin J., MD: C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene – C(H), SP(H); Demira – C(H); Dr Reddy's Laboratory – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Leo Pharma Inc – C(H); Novartis – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Promius Pharma, LLC – C(H); Regeneron – C(H), SP(H); Sanofi Genzyme – SP(H); Sun Pharmaceutical Industries Ltd. – C(H), SP(H); UCB – C(H), SP(H); Valeant Pharmaceuticals North America LLC – C(H), SP(H);
Friday, February 16
9:00 AM
Dr. Wu / Welcome and introduction
9:05 AM
Egeberg / Psoriasis: comorbidities
9:25 AM
Dr. Silverberg / Atopic dermatitis: comorbidities
9:45 AM
Dr. Koo / Psoriasis: oral therapy, topical therapy, and phototherapy
10:10 AM
Dr. Simpson / Atopic dermatitis: therapy
10:35 AM
Dr. Wu / Psoriasis: biologics
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 23C
  • CME Credits
  • Type
  • Jashin J. Wu, MD, FAAD
  • Alexander Egeberg, MD, PhD
  • Eric Lawrence Simpson, MD, FAAD
  • John Y. M. Koo, MD, FAAD
  • Jonathan I. Silverberg, MD, PhD, MPH, FAAD